Learn About Brain Stem Cancer

What is the definition of Brain Stem Cancer?
Brainstem cancers are usually astrocytomas or gliomas that are classified by their location in different areas of the brainstem and include focal brainstem gliomas, diffuse intrinsic pontine gliomas (DIPG), and diffuse midline gliomas. Depending on the type and location, brainstem cancers may progress slowly or rapidly, range from grades I–IV, and may occur in children and adults.
Save information for later
Sign Up
What are the symptoms of Brain Stem Cancer?
The brainstem controls such critical functions as swallowing, blood pressure, heart rate, breathing, and the muscles and nerves that control talking, eating, walking, hearing, and seeing. For this reason, the signs and symptoms of brainstem cancer may include headache, nausea and vomiting, balance problems, numbness or weakness of the limbs, facial paralysis, double vision, difficulty swallowing (dysphagia), and difficulty talking. Symptoms may come on suddenly and progress rapidly within a day or so, while some patients may experience no symptoms at all or symptoms that slowly progress.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Brain Stem Cancer?
While some patients may be initially placed under observation until signs and symptoms appear, treatment of brainstem gliomas include surgery, radiation therapy (external or internal), chemotherapy, and cerebrospinal fluid diversion. Surgery may not always be possible due to the tumor’s location in the brainstem, in which case radiation treatment is started. Chemotherapy may be added to radiation therapy or administered after. Cerebrospinal fluid diversion involves the use of a shunt implanted in a ventricle of the brain to siphon off excess fluid from the brain. New targeted therapies for the treatment of brainstem gliomas are currently under investigation.
Who are the top Brain Stem Cancer Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Brain Stem Cancer Clinical Trials?
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Summary: This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1 Trial of Marizomib Alone and in Combination With Panobinostat for Children With Diffuse Intrinsic Pontine Glioma

Summary: This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: Marizomib Panobinostat

What are the Latest Advances for Brain Stem Cancer?
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review.
Tired of the same old research?
Check Latest Advances
Isolated facial diplegia as an atypical variant of Guillain-Barre syndrome after suspected SARS-CoV-2 infection
What are some Advocacy Organizations?

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.